title: Induction therapy for patients with multiple sclerosis: why? When? How?
abstract: The concept of induction treatment followed by long-term maintenance treatment in multiple sclerosis (MS) has attracted considerable attention. The combination of mitoxantrone as the induction therapy followed by an immunomodulatory drug (e.g., interferon beta or glatiramer acetate) as the maintenance therapy is of particular interest. This approach is suitable for patients with particularly aggressive disease, characterised by frequent relapses with incomplete recovery and the accumulation of focal lesions visible on magnetic resonance imaging. A long-term study has shown that a short (6 month) course of mitoxantrone followed by maintenance therapy with an immunomodulatory drug brings about a rapid reduction in disease activity and subsequent sustained disease control for at least 5 years. Furthermore, randomised studies have demonstrated that induction with mitoxantrone followed by maintenance treatment affords better disease control than monotherapy with an interferon beta. Natalizumab is also effective in patients with very active MS, but has a propensity to result in rebound inflammatory disease activity on withdrawal. More recently, a mere 5-day course of 12-mg intravenous perfusions of alemtuzumab was found to bring long-term clinical benefits in early relapsing MS patients at risk of developing severe systemic autoimmune disease within the space of a few years.
authors: Department of Neurology, CIC-P 02-03 INSERM, INCR, CHU Pontchaillou, 35033, Rennes Cedex, France. gilles.edan@chu-rennes.fr
authors: Gilles
authors: G
authors: Edan
authors: Emmanuelle
authors: E
authors: Le Page
mesh_terms: D004334:Drug Administration Schedule; D000068717:Glatiramer Acetate; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D060046:Maintenance Chemotherapy / Q000379:methods; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D064887:Observational Studies as Topic; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone
references: Lancet. 2012 Nov 24;380(9856):1819-28
references: 23122652
references: Ther Adv Neurol Disord. 2012 Mar;5(2):75-9
references: 22435072
references: J Clin Oncol. 1997 Dec;15(12):3488-95
references: 9396402
references: Acta Neurol Scand. 2013 Aug;128(2):e6-e10
references: 23336398
references: N Engl J Med. 2008 Oct 23;359(17):1786-801
references: 18946064
references: Neurology. 2011 Aug 9;77(6):573-9
references: 21795656
references: N Engl J Med. 2006 Jan 12;354(2):166-78
references: 16407512
references: Lancet. 2012 Nov 24;380(9856):1829-39
references: 23122650
references: J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1344-50
references: 21436229
references: J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6
references: 17846110
references: Brain. 2008 Mar;131(Pt 3):808-17
references: 18234696
references: Mult Scler. 2012 Feb;18(2):143-52
references: 22312009
references: Ann Neurol. 2009 Mar;65(3):239-48
references: 19334069
references: J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):112-8
references: 9048709
references: Neurology. 2011 Nov 22;77(21):1887-95
references: 22076543
references: Neurology. 2004 Nov 23;63(10):1788-95
references: 15557491
references: Mult Scler. 2011 Jul;17(7):867-75
references: 21325016
references: J Neurol. 2009 Mar;256(3):405-15
references: 19308305
references: Neurol Sci. 2008 Sep;29 Suppl 2:S253-5
references: 18690509
references: Brain. 2010 Jul;133(Pt 7):1914-29
references: 20534650
references: N Engl J Med. 2006 Mar 2;354(9):899-910
references: 16510744
references: Mult Scler. 2008 Jun;14(5):663-70
references: 18424479
references: J Neurol Sci. 2011 Sep 15;308(1-2):98-102
references: 21665227
references: Neurology. 2012 Apr 3;78(14):1069-78
references: 22442431
references: Brain. 2010 Jul;133(Pt 7):1900-13
references: 20423930
references: J Neurol Sci. 2009 Feb 1;277 Suppl 1:S42-5
references: 19200866
references: J Neurol. 2006 Jan;253(1):98-108
references: 16044212